Aurobindo Pharma has received approval from board of directors for sale and transfer of all equity shares of Auro Vaccines, a wholly owned subsidiary of the Company, to Curateq Biologics, another wholly owned subsidiary of the Company, as part of verticalization of business operations. The completion of the sale is estimated in the first quarter of FY 2023-24. The Board of Directors of Aurobindo Pharma at its meeting held on May 27, 2023, has approved the same.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
